By T. Trano. Lasell College.
One trial 123 directly compared tizanidine to chlorzoxazone viagra soft 50 mg generic, one trial compared cyclobenzaprine to 20 124 methocarbamol order viagra soft 100mg overnight delivery, and one trial compared cyclobenzaprine to carisoprodol. Of nine trials that compared an included skeletal muscle relaxant to diazepam, five trials reported in four 125-128 129 51 publications evaluated cyclobenzaprine, one trial evaluated carisoprodol, one trial 130, 131 evaluated chlorzoxazone, and two trials evaluated tizanidine. We identified no head-to- head trials of orphenadrine, metaxalone, dantrolene, or baclofen in patients with 132 musculoskeletal conditions. One trial was excluded because it evaluated an included skeletal muscle relaxant versus chlormezanone, a medication not available or approved in the United States. Six others were excluded because they only evaluated the combination of a 22, 133- skeletal muscle relaxant and analgesic, or did not use an equivalent analgesic in each arm. All focused on patients with back or neck pain and spasms. The duration of all head-to-head trials was short, ranging from seven 126 130 to 18 days. The remainder enrolled outpatients or did not specify whether enrollees were in- or 129 outpatients. All were single center trials except one multicenter trial. Race was reported in 20, 124, 129 three trials and non-whites accounted for <15% of patients in these trials. Percentage 130 20 of female patients enrolled ranged from 30% to over 55%. The average age of enrollees ranged from 37 to 52 years. Although elderly patients were included in most head-to-head trials, no trial specifically evaluated only elderly patients and none included children. Three trials evaluated a skeletal muscle relaxant with an equivalent 148, 155, 159 analgesic in each arm and were included. Most trials evaluated low back or neck syndromes alone or mixed with other musculoskeletal conditions. Other conditions 58, 145, 149, 151 specifically evaluated were fibromyalgia, tension headaches or mixed headache 45, 150, 162, 164 154 conditions, and nocturnal leg cramps. No placebo-controlled trials included 162 154 children. One trial of tension headaches only included women and one trial evaluated orphenadrine in elderly patients with nocturnal leg cramps. What is the comparative efficacy of different muscle relaxants in reducing symptoms and improving functional outcomes in patients with a chronic neurologic condition associated with spasticity, or a chronic or acute musculoskeletal condition with or without muscle spasms? Patients with spasticity Summary There is fair evidence from nine fair-quality head-to-head trials and one fair-quality meta-analysis of eight unpublished trials that tizanidine and baclofen are roughly equivalent for clinical efficacy. There is inadequate evidence from head-to-head or placebo-controlled trials to assess the comparative efficacy of dantrolene against that of tizanidine or baclofen. In trials that have directly compared baclofen, tizanidine, or dantrolene to diazepam, efficacy of each medication appears to be similar to diazepam. There is fair-quality evidence from placebo- controlled trials that tizanidine, baclofen, and dantrolene are effective in the treatment of spasticity, though lack of high quality studies, heterogeneous outcome measures, and differences in populations limit further interpretation of these findings. There is insufficient evidence from clinical trials that other skeletal muscle relaxants, which have only been approved for use in musculoskeletal conditions, are effective for treatment of spasticity. Our 59, 61, 63 findings are similar to those of three recent good-quality systematic reviews. Results of systematic reviews and meta-analyses Two recent good-quality systematic reviews evaluated the efficacy of different skeletal 59, 61 muscle relaxants in patients with multiple sclerosis (Table 1, Evidence Table 1). Both found that the overall quality of studies were poor, with a wide variety of outcome measures used. They found limited evidence that baclofen, dantrolene, and tizanidine are effective for treatment of spasticity, limited evidence on functional outcomes, and insufficient evidence to determine whether one drug was superior to others.
Bongartz T generic 100mg viagra soft fast delivery, Warren FC generic viagra soft 50 mg amex, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Tumor necrosis factor (alpha) antagonist use and cancer in patients with rheumatoid arthritis. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Malignancies in the rheumatoid arthritis abatacept clinical development program: An epidemiological assessment. Haematopoietic malignancies in rheumatoid arthritis: Lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies: Systematic Review and Meta-analysis of Rare Harmful Effects in Randomized Controlled Trials. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Targeted immune modulators 137 of 195 Final Update 3 Report Drug Effectiveness Review Project 322. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person- years of observation. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Abatacept for rheumatoid arthritis: a Cochrane systematic review. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Tumor necrosis factor-(alpha) antagonist use and heart failure in elderly patients with rheumatoid arthritis. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Antirheumatic drug use and the risk of acute myocardial infarction. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Drug-induced systemic lupus erythematosus associated with etanercept therapy.
Diastolic blood pressure was not equivalent between groups safe 100mg viagra soft, and was statistically lower in those on maximum dose combination therapy as compared with valsartan monotherapy (P=0 generic viagra soft 100 mg without prescription. Adverse events were reported by treatment group by percent effected. Total percent of adverse events was numerically greatest among those on monotherapy with valsartan (45%), and DRIs, AIIRAs, and ACE-Is Page 66 of 144 Final Report Drug Effectiveness Review Project was similar among those on full and half dose combination therapy (25% and 33. Statistical analysis of adverse event rates between groups was not reported, but the event rate of hyperkalemia (potassium greater than 6 millimoles per liter) was highest among those on maximum dose combination therapy (11. Additional percent rates for treatment groups can be found in Evidence Table 9, although no statistical comparison is reported. Diabetic Nephropathy Summary of findings Comparison of aliskiren to placebo when added to an AIIRAs or ACE-Is • When added to losartan o Effectiveness/Efficacy: When added to losartan, aliskiren was superior to placebo in reducing urinary albumin-to-creatinine ratio, which appeared independent of change in systolic blood pressure. Analysis of correlation with diastolic blood pressure was not reported. Additionally, a significantly greater proportion of participants achieved a reduction of 50% or more in albuminuria in the aliskiren group. The differences between aliskiren and placebo in deaths, change in estimated glomerular filtration rate or overall withdrawals were not significant, however. Comparison of AIIRA and ACE-I monotherapies Effectiveness/efficacy/harms • Telmisartan compared with enalapril (1 trial, fair quality) o With a sample size of 250 participants and a follow-up period of 5 years, the Diabetics Exposed to telmisartan and enalapril (DETAIL) trial is the largest and longest-term trial that compared monotherapy with an AIIRA and an ACE-I in adults with diabetes. Telmisartan and enalapril also had similar effects on other secondary outcomes including all-cause mortality, death due to cardiovascular causes, nonfatal myocardial infarction, congestive heart failure, cerebrovascular accident, kidney failure/required dialysis, increased serum creatinine (greater than 2. Consistent findings of no differences in reduction of albumin levels DRIs, AIIRAs, and ACE-Is Page 67 of 144 Final Report Drug Effectiveness Review Project or change in glomerular filtration rate across 2 trials. Consistent findings of no differences in overall withdrawals across 3 trials. One trial each evaluated change in creatinine, creatinine clearance, and regression of microalbuminuria to normo albuminuria and found no differences between drugs. Three additional, smaller trials found no differences between drugs in various other drug-related adverse events. No significant difference in change in serum creatinine. Subgroups • No trials reported subgroup analyses based on demographics, comorbidities, or concomitant medication use. Combination therapy with AIIRAs and ACE-Is • Effectiveness/Efficacy DRIs, AIIRAs, and ACE-Is Page 68 of 144 Final Report Drug Effectiveness Review Project o Overall: No trials reported health outcomes, including all-cause mortality, development of chronic kidney disease, end-stage renal function, need for dialysis or transplantation, hospitalizations, or quality of life o Losartan plus enalapril (2 trials, both fair quality): Results did not clearly establish that combination therapy had a significantly greater benefit over monotherapy for decrease in urinary protein excretion that was independent from blood pressure control, regression from microalbuminuria to normo albuminuria, creatinine clearance, or overall withdrawals. However, independence from superior overall blood-pressure control was not established. No advantage for combination therapy in albumin, serum creatinine or creatinine clearance. No advantage for combination therapy in glomerular filtration rate or creatinine. No significant advantage was found for combination therapy in effects on creatinine, but there was noted to be a significantly greater reversible reduction in glomerular filtration rate during the 8- week study period. Detailed assessment Aliskiren used in combination with an AIIRA or an ACE-I We included 1, fair-quality, multicenter, international trial, the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial, that compared treatment with aliskiren (150 mg for 3 DRIs, AIIRAs, and ACE-Is Page 69 of 144 Final Report Drug Effectiveness Review Project months, then increased to 300 mg for another 3 months) or placebo, in addition to losartan 100 118 mg in 599 adults with type 2 diabetes and macroalbuminuria. Effectiveness/efficacy The primary efficacy measure was the percentage reduction in the early-morning urinary albumin-to-creatinine ratio, which was 20% greater for aliskiren compared with placebo (95% CI, 11 to 29). The greater reduction in urinary albumin-to-creatinine ratio for aliskiren decreased slightly, but remained significant after adjustment for change in systolic blood pressure (18%; 95% CI, 5 to 30). Results following adjustment for change in diastolic blood pressure were not reported. As for secondary outcomes, a significantly greater proportion of participants in the aliskiren group achieved a reduction of 50% or more in albuminuria (25% compared with 12%, P<0. Incidence of overall withdrawals was similar for aliskiren (14%) compared with placebo (11%). Harms In both treatment groups, incidence of overall adverse events was 67% and 6% of participants withdrew due to adverse events. There were no significant differences between aliskiren and placebo in incidence of hypotension (4% compared with 1%), hyperkalemia (5% compared with 6%), cough (2% in both groups), peripheral edema (4% compared with 8%), diarrhea (3% in both groups), or any other specific adverse events.
A second observational study of 633 patients evaluated the risk of major bleeding with aspirin plus clopidogrel compared with aspirin alone when given early after stroke or transient 57 ischemic attack order viagra soft 100mg. However order 50mg viagra soft, its results will not be discussed here because it had significant differences in clinical characteristics between groups at baseline but conducted no statistical analysis to adjust for these potential confounders. Ticlopidine compared with aspirin 45, 46 Among 2 randomized controlled trials, differences in harms between ticlopidine and aspirin only reached statistical significance in the larger (N=3069), longer-term (40 months) TASS trial, which involved a higher dosage in the aspirin control group (1300 mg) and enrolled primarily 46 white patients (80%). In the TASS trial, when compared to 1300 mg of aspirin, there was a significantly lower risk of gastrointestinal bleeding with ticlopidine (0. However, withdrawals due to adverse events were significantly greater with ticlopidine (21% compared with 14%; relative risk, 1. In contrast, in the 2-year AAASPS trial of 1809 black patients, when compared to aspirin 650 mg, ticlopidine had similar rates of gastrointestinal bleeding (0. Peripheral vascular disease Indirect evidence Clopidogrel compared with aspirin In the CAPRIE trial, data on harms were not reported separately for the subgroup of 11 592 24 patients with peripheral vascular disease. Clopidogrel plus aspirin compared with aspirin alone Two trials were consistent in finding no significant increase in major bleeding with clopidogrel 52, 53 plus aspirin compared with aspirin alone. In the subset of 3096 patients from the CHARISMA trial, rate of severe bleeding was identical for clopidogrel plus aspirin and aspirin 53 alone (1. In the CASPAR trial (N=851), the 1-year (median) incidence of severe bleeding was close to doubled during dual therapy with clopidogrel 75 mg plus aspirin (range, 75 mg to 100 mg) as compared with aspirin alone (range, 75 mg to 100 mg), but the difference was not statistically significant (2. Incidence of withdrawal due to adverse events was not reported. Newer antiplatelet agents 36 of 98 Final Update 2 Report Drug Effectiveness Review Project Key Question 3. For adults with acute coronary syndromes or coronary revascularization via stenting or bypass grafting, prior ischemic stroke or transient ischemic attack, or symptomatic peripheral vascular disease do antiplatelet agents differ in effectiveness and harms based on duration of therapy? Summary of Findings • We found no head-to-head trials that directly compared newer antiplatelet agents based on duration of therapy. The benefit appeared to decrease in a step-wise manner and lose statistical significance at 8 months (PCI-CURE, low strength) and 12 months (CREDO, moderate strength). Detailed Assessment Indirect evidence 5 Current percutaneous coronary intervention guidelines recommend the duration of thienopyridine therapy for patients receiving a bare metal stent or drug eluting stent during percutaneous coronary intervention for acute coronary syndrome be at least 12 months. If the risk of morbidity because of bleeding outweighs the anticipated benefit afforded by thienopyridine therapy, earlier discontinuation should be considered. Early discontinuation of thienopyridine therapy has been identified as a risk factor for late stent thrombosis in patients with drug eluting stent but the optimal therapy and comparative risk-benefit of bare metal stent 58, 59 compared with drug eluting stent remains uncertain. This controversy is beyond the scope of this report. Among the 3 trials that evaluated 6 months of dual therapy, the first evaluated clopidogrel 75 mg plus aspirin 100 mg in 278 Turkish patients with successful stent 62 implantation. The second trial evaluated clopidogrel 75 mg plus aspirin 300 mg in 78 Turkish patients with typical stable angina pectoris or documented myocardial ischemia, and with only 1 60 angiographic lesion in 1 native coronary artery undergoing successful stent implantation. The Randomized Argentine Clopidogrel Stent (RACS) trial was a prospective, randomized, nonblinded study of 1004 patients undergoing percutaneous coronary intervention who were randomized after successful bare metal stent placement to 30 compared with 180 days of 61 clopidogrel 75 mg plus aspirin 75 to 325 mg. The PCI-CURE trial included 2658 patients with 63 non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention. Following percutaneous coronary intervention, after 2 to 4 weeks of open-label clopidogrel or ticlopidine, patients were randomized to a mean of 8 months of continuing treatment with clopidogrel plus aspirin 75 to 325 mg or to placebo. Similarly, in the CREDO trial, after percutaneous coronary intervention, 2116 patients received open-label clopidogrel 75 mg for 28 Newer antiplatelet agents 37 of 98 Final Update 2 Report Drug Effectiveness Review Project days and then were randomly assigned to double blind treatment with continuation of clopidogrel 64 75 mg plus aspirin 325 mg for 12 months or to aspirin 325 mg alone. When we used a fixed-effects model to pool data from the 3 trials that compared 6 months of treatment with clopidogrel plus aspirin to 1 month of treatment for the outcomes of all-cause mortality, cardiovascular mortality, revascularization, and bleeding, a significant benefit with the longer-term treatment was only found for the outcome of revascularization (relative risk, 0. No other pooled outcome reached statistical significance. Only the RACS trial reported withdrawals due to adverse events but it was a nonsignificant and imprecise finding 61 (relative risk, 2. In contrast, when we considered results for revascularization from the PCI-CURE and CREDO trials, we observed that the potential benefit of a reduced risk of revascularization became only probable at 8 months was unlikely at 12 months (Table 4, Figure 2). There was also a trend toward increased bleeding risk over time when results from the PCI-CURE and CREDO trials were considered (Table 4, Figure 3). Detailed outcome data from pooled analysis of dual antiplatelet therapy length postpercutaneous coronary intervention All-cause Cardiovascular mortality mortality Revascularization Bleeding Therapy (95% confidence (95% confidence (95% confidence (95% confidence length N interval) interval) interval) interval) 64,65 1199 0. Newer antiplatelet agents 38 of 98 Final Update 2 Report Drug Effectiveness Review Project Figure 2.
8 of 10 - Review by T. Trano
Votes: 190 votes
Total customer reviews: 190